A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models
Name:
A_Novel_Mu-Delta_Opioid_Agonist.pdf
Size:
1.134Mb
Format:
PDF
Description:
Final Accepted Manuscript
Affiliation
Univ Arizona, Coll Med, Dept PharmacolIssue Date
2020-01Keywords
Mu opioid receptordelta opioid receptor
HIV neuropathy
chemotherapy-induced neuropathy
tolerance
dependence
neuroinflammation
Metadata
Show full item recordPublisher
Elsevier BVCitation
Lei, W., Vekariya, R. H., Ananthan, S., & Streicher, J. M. (2020). A novel mu-delta opioid agonist demonstrates enhanced efficacy with reduced tolerance and dependence in mouse neuropathic pain models. The Journal of Pain, 21(1-2), 146-160.Journal
JOURNAL OF PAINRights
Copyright © 2020 U.S. Association for the Study of Pain. Published by Elsevier Inc. All rights reserved.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Numerous studies have demonstrated a physiological interaction between the mu opioid receptor (MOR) and delta opioid receptor (DOR) systems. A few studies have shown that dual MOR-DOR agonists could be beneficial, with reduced tolerance and addiction liability, but are nearly untested in chronic pain models, particularly neuropathic pain. In this study, we tested the MOR-DOR agonist SRI-22141 in mice in the clinically relevant models of HIV Neuropathy and Chemotherapy-Induced Peripheral Neuropathy (CIPN). SRI-22141 was more potent than morphine in the tail flick pain test and had equal or enhanced efficacy versus morphine in both neuropathic pain models, with significantly reduced tolerance. SRI-22141 also produced no jumping behavior during naloxone-precipitated withdrawal in CIPN or nayve mice, suggesting that SRI-22141 produces little to no dependence. SRI-22141 also reduced tumor necrosis factor-alpha and cyclooxygenase-2 in CIPN in the spinal cord, suggesting an anti-inflammatory mechanism of action. The DOR-selective antagonist naltrindole strongly reduced CIPN efficacy and anti-inflammatory activity in the spinal cord, without affecting tail flick antinociception, suggesting the importance of DOR activity in these models. Overall, these results provide compelling evidence that MOR-DOR agonists could have strong efficacy with reduced side effects and an anti-inflammatory mechanism in the treatment of neuropathic pain. Perspective: This study demonstrates that a MOR-DOR dual agonist given chronically in chronic neuropathic pain models has enhanced efficacy with strongly reduced tolerance and dependence, with a further anti-inflammatory effect in the spinal cord. This suggests that MOR-DOR dual agonists could be effective treatments for neuropathic pain with reduced side effects. (C) 2020 U.S. Association for the Study of Pain. Published by Elsevier Inc. All rights reserved.Note
12 month embargo; published 12 June 2019ISSN
1526-5900PubMed ID
31201990Version
Final accepted manuscriptSponsors
National Institutes of Healthae974a485f413a2113503eed53cd6c53
10.1016/j.jpain.2019.05.017
Scopus Count
Collections
Related articles
- In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.
- Authors: Lowery JJ, Raymond TJ, Giuvelis D, Bidlack JM, Polt R, Bilsky EJ
- Issue date: 2011 Mar
- In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
- Authors: Wells JL, Bartlett JL, Ananthan S, Bilsky EJ
- Issue date: 2001 May
- Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.
- Authors: Podolsky AT, Sandweiss A, Hu J, Bilsky EJ, Cain JP, Kumirov VK, Lee YS, Hruby VJ, Vardanyan RS, Vanderah TW
- Issue date: 2013 Dec 18
- The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment.
- Authors: Pasquinucci L, Parenti C, Turnaturi R, Aricò G, Marrazzo A, Prezzavento O, Ronsisvalle S, Georgoussi Z, Fourla DD, Scoto GM, Ronsisvalle G
- Issue date: 2012 Jan 2
- Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
- Authors: Vekariya RH, Lei W, Ray A, Saini SK, Zhang S, Molnar G, Barlow D, Karlage KL, Bilsky EJ, Houseknecht KL, Largent-Milnes TM, Streicher JM, Ananthan S
- Issue date: 2020 Jul 23
